福辛普利通过抑制TLR4/NF-κB/NLRP3信号通路减轻糖尿病干眼模型的炎症反应
本研究在高糖诱导的人角膜上皮(HCE-T)细胞和链脲佐菌素(STZ)诱导的C57BL/6小鼠两种糖尿病干眼模型中,探讨TLR4/NF-κB/NLRP3信号通路的参与机制,并使用TLR4抑制剂福辛普利(FOS)抑制该通路。结果显示糖尿病干眼模型中TLR4、NF-κB、NLRP3及IL-1β转录水平升高,FOS可下调这些通路因子,并提高高糖诱导HCE-T细胞划痕愈合率、增加糖尿病小鼠泪液分泌、降低角膜荧光染色评分。
要点
- 糖尿病干眼模型中TLR4/NF-κB/NLRP3通路因子TLR4、NF-κB、NLRP3及IL-1β转录水平升高。
- TLR4抑制剂福辛普利可下调上述通路因子水平。
- 福辛普利提高高糖诱导HCE-T细胞划痕愈合率,增加糖尿病小鼠泪液分泌并降低角膜荧光染色评分。
核心结论
- 本研究发现TLR4/NF-κB/NLRP3信号通路在体外和体内模型中调控糖尿病干眼,福辛普利可减轻糖尿病小鼠干眼体征,为糖尿病干眼提供新的治疗选择。
研究设计与样本
- 研究建立高糖诱导的人角膜上皮(HCE-T)细胞和链脲佐菌素(STZ)诱导的C57BL/6小鼠两种糖尿病干眼模型,并使用TLR4抑制剂福辛普利(FOS)抑制TLR4/NF-κB/NLRP3信号通路。
主要发现
- 糖尿病干眼模型中TLR4、NF-κB、NLRP3及IL-1β转录水平升高,应用TLR4抑制剂FOS后这些通路因子水平下调。
- FOS提高高糖诱导HCE-T细胞的划痕愈合率。
- FOS增加糖尿病小鼠泪液分泌并降低角膜荧光染色评分。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this study was to investigate the involvement of the TLR4/NF-κB/NLRP3 signaling pathway and its underlying mechanism in diabetic dry eye. METHODS: Two models of diabetic dry eye were established in high glucose-induced human corneal epithelial (HCE-T) cells and streptozotocin (STZ)-induced C57BL/6 mice, and the TLR4 inhibitor fosfenopril (FOS) was utilized to suppress the TLR4/NF-κB/NLRP3 signaling pathway. The expression changes in TLR4, NF-κB, NLRP3, and IL-1β, and other factors were detected by Western blot and RT‒qPCR, the wound healing rate was evaluated by cell scratch assay, and the symptoms of diabetic mice were evaluated by corneal sodium fluorescein staining and tear secretion assay. RESULTS: In the diabetic dry eye model, the transcript levels of TLR4, NF-κB, NLRP3, and IL-1β were raised, and further application of FOS, a TLR4 inhibitor, downregulated the levels of these pathway factors. In addition, FOS was found to be effective in increasing the wound healing rate of high glucose-induced HCE-T cells, increasing tear production, and decreasing corneal fluorescence staining scores in diabetic mice, as measured by cell scratch assay, corneal sodium fluorescein staining assay, and tear production. CONCLUSIONS: The current study found that the TLR4/NF-κB/NLRP3 signaling pathway regulates diabetic dry eye in an in vitro and in vivo model, and that FOS reduces the signs of dry eye in diabetic mice, providing a new treatment option for diabetic dry eye.
引用
- Jiang K, Zhang F, Chen Y, et al. Fosfenopril Attenuates Inflammatory Response in Diabetic Dry Eye Models by Inhibiting the TLR4/NF-κB/NLRP3 Signaling Pathway. Invest Ophthalmol Vis Sci. 2024. PMID: 38829670. doi:10.1167/iovs.65.6.2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。